Vinva Investment Management Ltd Buys 1,157 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Vinva Investment Management Ltd raised its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,322 shares of the medical research company’s stock after acquiring an additional 1,157 shares during the period. Vinva Investment Management Ltd’s holdings in Thermo Fisher Scientific were worth $11,257,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TMO. Financial Counselors Inc. boosted its holdings in Thermo Fisher Scientific by 0.9% during the third quarter. Financial Counselors Inc. now owns 79,722 shares of the medical research company’s stock worth $49,314,000 after purchasing an additional 696 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Thermo Fisher Scientific by 0.9% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,163,487 shares of the medical research company’s stock worth $1,338,268,000 after buying an additional 19,536 shares during the last quarter. Public Sector Pension Investment Board grew its holdings in shares of Thermo Fisher Scientific by 42.2% in the third quarter. Public Sector Pension Investment Board now owns 239,811 shares of the medical research company’s stock valued at $148,340,000 after acquiring an additional 71,140 shares in the last quarter. Fiduciary Trust Co lifted its holdings in Thermo Fisher Scientific by 0.3% during the third quarter. Fiduciary Trust Co now owns 66,668 shares of the medical research company’s stock worth $41,239,000 after acquiring an additional 196 shares during the period. Finally, Providence Capital Advisors LLC boosted its position in Thermo Fisher Scientific by 31.5% in the third quarter. Providence Capital Advisors LLC now owns 13,752 shares of the medical research company’s stock worth $8,507,000 after purchasing an additional 3,296 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Stifel Nicolaus lowered their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research note on Thursday, October 24th. UBS Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Monday, September 16th. JPMorgan Chase & Co. raised their price target on shares of Thermo Fisher Scientific from $650.00 to $670.00 and gave the stock an “overweight” rating in a research note on Friday, September 20th. Robert W. Baird dropped their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Finally, Royal Bank of Canada decreased their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $649.33.

Thermo Fisher Scientific Stock Up 1.7 %

Shares of NYSE:TMO opened at $521.66 on Thursday. The company has a market cap of $199.53 billion, a price-to-earnings ratio of 32.71, a PEG ratio of 3.40 and a beta of 0.79. Thermo Fisher Scientific Inc. has a one year low of $480.57 and a one year high of $627.88. The firm has a fifty day moving average price of $569.98 and a two-hundred day moving average price of $578.78. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. The business had revenue of $10.60 billion for the quarter, compared to analyst estimates of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The company’s quarterly revenue was up .2% compared to the same quarter last year. During the same period in the prior year, the company earned $5.69 EPS. Analysts anticipate that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be paid a $0.39 dividend. The ex-dividend date is Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.30%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 9,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $552.86, for a total transaction of $4,975,740.00. Following the transaction, the chief executive officer now directly owns 14,608 shares of the company’s stock, valued at approximately $8,076,178.88. This trade represents a 38.12 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This trade represents a 1.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,150 shares of company stock valued at $20,651,865 in the last quarter. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.